ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Treg cells"

  • Abstract Number: 0423 • ACR Convergence 2023

    Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis

    Sara Charmsaz1, Jeff Tracy1, Elizabeth Whalen1, John Bui1, Anne-Renee van der Vuurst de Vries1, Vivianne Malmström2 and Michelle Blake1, 1Sonoma Biotherapeutics, Seattle, WA, 2Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…
  • Abstract Number: 0799 • ACR Convergence 2023

    Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus

    Holly Wobma1, Xianliang Rui2, Francesca Alvarez-Calderon2, Ulrike Gerdemann2, Connor McGuckin2, Bruce Blazar3, Victor Tkachev4 and Leslie Kean2, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, 3Division of Pediatric Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, 4Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Chimeric Antigen Receptor Regulatory T cells (CAR-Tregs) are an emerging strategy to restore immune tolerance during auto- or allo-immune conditions. However, most autoimmune diseases…
  • Abstract Number: 0887 • ACR Convergence 2023

    Dapagliflozin Modulates Inflammation and Germinal Centers in Lupus by Increasing Regulatory T Cells

    Javier Rangel-Moreno1, Maria de la Luz Garcia-Hernandez2, Mary O'Connell3, Daria Krenitsky4, Maria Fernanda Ossa-Echeverri1, Mark Lusco5, John Looney6 and Jennifer Anolik3, 1University of Rochester, Rochester, NY, 2University of Rochester, West Henrietta, NY, 3University of Rochester Medical Center, Rochester, NY, 4Division of Allergy, Immunology and Rheumatology/University of Rochester Medical Center, Rochester, NY, 5Department of Pathology and Laboratory Medicine/University of Rochester, Rochester, NY, 6Division of Allergy, Immunology and Rheumtology, Rochester, NY

    Background/Purpose: Nephritis is one of the most severe manifestations of lupus, affecting 40-70% of patients. Though immune-targeted therapies have improved, a significant number of patients…
  • Abstract Number: 1311 • ACR Convergence 2023

    T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis

    Huaqun Zhu1, Sumei Tang1, Gong Cheng1, Yingni Li1, Yun Li1, Feng Sun1, Xiaolin Sun1, Jiahui Cheng1, Ru Li1 and Zhanguo Li2, 1Peking University People’s Hospital, Beijing, China, 2Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China

    Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
  • Abstract Number: 1366 • ACR Convergence 2023

    A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease

    Myung-Chul Kim1, Umasankar De2, Nicholas Borcherding3, Joon Paek4, Nicole Winn5, Indraneel Bhattacharyya6, Qing Yu7, Ryan Kolb8, Theodore Drashansky9, Akaluck Thatayatikom10, Weizhou Zhang8 and Seunghee Cha11, 1Jeju National University, Jeju-si, South Korea, 2University of Florida, Gainesville, FL, 3Washington University School of Medicine in St. Louis, Washington, DC, 4Department of Oral & Maxillofacial Diagnostic Sciences, Gainesville, FL, 5Division of Oral Medicine, Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, 6Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, 7The Forsyth Institute, Cambridge, MA, 8Department of Pathology & Immunology, University of Florida, Gainesville, FL, 9Cellularity, Inc, Florham Park, NJ, 10AdventHealth for Children, Orlando, FL, Orlando, FL, 11Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL

    Background/Purpose: This study was performed to characterize key immune cell subsets and their interactions in patients with childhood Sjögren's disease (cSjD) for the first time…
  • Abstract Number: 1373 • ACR Convergence 2023

    Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome

    Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Background/Purpose: Deltex1 is a transcription target of nuclear factor of activated T cells in mice and promotes T cell anergy. We have previously reported that…
  • Abstract Number: 1560 • ACR Convergence 2023

    Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China

    Jiachen Li1, Feng Sun2, Wenyan Zhou1 and Tian Liu1, 1Peking University People's Hospital, Beijing, China, 2Peking University People’s Hospital, Beijing, China

    Background/Purpose: Behcet's syndrome (BS) is an autoimmune disease characterized by recurrent mucocutaneous ulcerations, vascular and nervous system involvement. While there have been a lot of…
  • Abstract Number: 1707 • ACR Convergence 2023

    PD1-Expressing Regulatory T Cells Found in Inflamed Joints Suppress Tph Cell-B Cell Interactions

    Ki Pui Lam1, Amélie M Julé1, Claudia Harris2, Maria Taylor1, Maryrose Hahn2, Laurie A Ohlms3, Pui Lee2, Margaret Chang4, Talal Chatila5, Peter Nigrovic4 and Lauren Henderson4, 1Division of Immunology, Boston Children’s Hospital, Boston, MA, 2Division of Immunology, Boston Children's Hospital, Boston, MA, 3Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital, Boston, MA, 4Boston Children's Hospital, Boston, MA, 5Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: T peripheral helper (Tph) cells promote B cell maturation and the generation of antibodies in the inflamed joints of adults with seropositive rheumatoid arthritis…
  • Abstract Number: 1756 • ACR Convergence 2023

    Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis

    Maria-Eugenia Miranda-Carus1, Beatriz Nieto-Carvalhal1, Alejandro Villalba2, Laura Nuño1, Marta Benito-Miguel3, Marta Novella-Navarro4, Irene Monjo5, Diana Peiteado1, Sara García-Carazo1 and Alejandro Balsa4, 1Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 2Rheumatology Department, La Paz University Hospital, Madrid, Spain, 3Universidad Nebrija, Physiology, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5University Hospital La Paz, Madrid, Spain

    Background/Purpose: A subset of human FoxP3+ regulatory T (Treg) cells expresses CD39 (Treg39+) and hydrolyses proinflammatory adenine nucleotides released at inflammatory foci, rendering the antiinflamatory…
  • Abstract Number: 2337 • ACR Convergence 2023

    Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

    Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA

    Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
  • Abstract Number: 2444 • ACR Convergence 2023

    Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis

    Eric Morand1, Rachel Cheong2, Peter Eggenhuizen2, Janet Chang2, Ashraf Broury2, Boaz Ng2, Khai Loh2, Elean Tay2, Chanjuan Shen3, Julie Monk2, Yong Zhong4, Steven Lim2, Jia Xi Chung2, Rangi Kandane-Rathnayake5, Rachel Koelmeyer2, Alberta Hoi6, Sarah Snelgrove2, Yi Tian Ting2 and Joshua Ooi2, 1Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, 2Monash University, Clayton, Australia, 3Central South University, Changsha, China, 4Xiangya Hospital, Central South University, Changsha, China, 5Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, 6Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia

    Background/Purpose: Regulatory T cells (Tregs) play an important role in maintaining immune system homeostasis. Antigen-specific Tregs potently and specifically suppress autoreactivity, suggesting their potential to…
  • Abstract Number: 0581 • ACR Convergence 2022

    Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders

    Yingying Hu1, Hu Ge1, Yuxi Yan1, Yun Zhang2, Xiaoxing Huang1, Zhenna Gao2, Yiming Kou2, Mi Ye2, Lei Zhou1, Siyuan Shao1, Bowei Yin1, Zhenzhen Li1, Yayuan Fu1, Wenqing Yang1, Zhuoxiao Cao1 and Renhong Tang1, 1Simcere Pharmaceutical Group, Shanghai, China, 2Simcere Pharmaceutical Group, Nanjing, China

    Background/Purpose: Low-dose IL-2 with enhanced sensitivity to Treg cells has been proved to be safe and efficacious in multiple autoimmune disorders (AIDs) including SLE, RA,…
  • Abstract Number: 0646 • ACR Convergence 2022

    Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway

    Ruth Fernandez Ruiz1, Ilona Nln2, Jacqueline Paredes2 and Timothy Niewold2, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: IFNα is a pathogenic factor in SLE. The PRKG1 rs7897633 variant has been previously identified as the top hit in European ancestry patients with…
  • Abstract Number: 0649 • ACR Convergence 2022

    Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity

    Marc Scherlinger1, Wenliang Pan2, Ryo Hisada1, Milena Vukelic3, Masataka Umeda1, Afroditi Boulougoura2, Maria Tsokos1 and George Tsokos2, 1BIDMC Harvard University, Boston, MA, 2Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
  • Abstract Number: 0666 • ACR Convergence 2022

    HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE

    Seong Hee (Joy) Park1, Akshay Patel2 and Andras Perl3, 1Upstate Medical University, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3SUNY, Syracuse, NY

    Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology